HomeNoNO Inc2022-11-23T19:45:01+00:00
DISCOVER NOW NoNO Inc. is on the brink of achieving one of the most ambitious goals in 21st century medicine: protecting the brain against stroke. Our scientists and physicians have been at the forefront of stroke science for two decades with an unrelenting commitment to improving life after stroke. Today, we are industry leaders changing the paradigm of stroke therapy. NEXT The Breakthrough Nerinetide, NoNO’s lead compound for people experiencing an ischemic stroke, currently completing its second global Phase 3 trial in people not previously treated with a clot dissolving drug. NEXT The Expansion
NoNO-42, in Phase 1 for use alongside clot dissolving drugs for all people experiencing ischemic stroke. The Future NoNO-SC administered subcutaneously to enable the treatment of people experiencing stroke outside of medical settings by anyone – anywhere. LEARN MORE